CL2015002666A1 - Formas de dosificación sólidas de antiemético de liberación prolongada - Google Patents

Formas de dosificación sólidas de antiemético de liberación prolongada

Info

Publication number
CL2015002666A1
CL2015002666A1 CL2015002666A CL2015002666A CL2015002666A1 CL 2015002666 A1 CL2015002666 A1 CL 2015002666A1 CL 2015002666 A CL2015002666 A CL 2015002666A CL 2015002666 A CL2015002666 A CL 2015002666A CL 2015002666 A1 CL2015002666 A1 CL 2015002666A1
Authority
CL
Chile
Prior art keywords
dosage forms
extended
solid dosage
release antiemetic
antiemetic
Prior art date
Application number
CL2015002666A
Other languages
English (en)
Spanish (es)
Inventor
Reza Fathi
Gilead Raday
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002666(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of CL2015002666A1 publication Critical patent/CL2015002666A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2015002666A 2013-03-14 2015-09-14 Formas de dosificación sólidas de antiemético de liberación prolongada CL2015002666A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361782395P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
CL2015002666A1 true CL2015002666A1 (es) 2017-02-17

Family

ID=51528070

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002666A CL2015002666A1 (es) 2013-03-14 2015-09-14 Formas de dosificación sólidas de antiemético de liberación prolongada

Country Status (19)

Country Link
US (5) US9636305B2 (enExample)
EP (1) EP2983664B1 (enExample)
JP (1) JP6282676B2 (enExample)
KR (1) KR102270521B1 (enExample)
CN (2) CN112274489A (enExample)
AU (1) AU2014264342B2 (enExample)
BR (1) BR112015022398B1 (enExample)
CA (1) CA2905553C (enExample)
CL (1) CL2015002666A1 (enExample)
ES (1) ES2946985T3 (enExample)
HK (1) HK1223012A1 (enExample)
IL (1) IL241580B (enExample)
MX (1) MX378261B (enExample)
NZ (1) NZ712159A (enExample)
PH (1) PH12015502093B1 (enExample)
RU (1) RU2679448C2 (enExample)
SG (1) SG11201507450TA (enExample)
WO (2) WO2014181195A2 (enExample)
ZA (1) ZA201506961B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2946985T3 (es) 2013-03-14 2023-07-31 Redhill Biopharma Ltd Formas farmacéuticas sólidas antieméticas de liberación prolongada
CA2941829C (en) * 2014-03-11 2021-11-02 Redhill Biopharma Ltd Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
WO2020080875A1 (ko) * 2018-10-19 2020-04-23 주식회사 삼양바이오팜 아프레피탄트의 경구용 조성물
GEAP202516774A (en) * 2022-11-03 2025-06-25 Lumos Pharma Inc Compactable oral formulations of ibutamoren

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4720353A (en) * 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US20020071863A1 (en) 1999-12-09 2002-06-13 Dong Liang C. Antiviral medication
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
WO2003024427A1 (en) 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US20020172712A1 (en) * 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
GB0119012D0 (en) * 2001-08-03 2001-09-26 Strakan Group Plc Transdermal delivery of drugs
GB0129489D0 (en) * 2001-12-10 2002-01-30 Quadrant Healthcare Uk Ltd Sustained-release compositions
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
JP2006516977A (ja) 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法
KR101052705B1 (ko) 2003-11-14 2011-08-01 센주 세이야꾸 가부시키가이샤 아미노글리코시드계 항생물질 및 브롬페낙을 함유하는수용액 제제
AU2005237360B2 (en) * 2004-04-30 2010-10-21 Astellas Pharma Inc. Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition
CA2590802A1 (en) * 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
CA2635313C (en) * 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080004260A1 (en) 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
ATE553754T1 (de) * 2006-08-18 2012-05-15 Evonik Roehm Gmbh Pharmazeutische zusammensetzung mit kontrollierter wirkstoffabgabe für wirkstoffe mit guter löslichkeit in wasser
CN100584319C (zh) 2006-10-16 2010-01-27 北京科信必成医药科技发展有限公司 群孔释放渗透泵控释片及其制备方法
AU2007308986A1 (en) * 2006-10-25 2008-05-02 Mcneil-Ppc, Inc. Ibuprofen composition
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
CN101568351B (zh) * 2006-12-22 2012-05-30 3M创新有限公司 控制释放的组合物和方法
WO2009118763A1 (en) 2008-03-28 2009-10-01 Panacea Biotec Limited Multilayered pharmaceutical compositions and processes thereof
US20100196291A1 (en) * 2009-01-30 2010-08-05 Laurence Halimi Personal care sunscreen compositions having reduced eye irritation
EP2403487A2 (en) * 2009-03-04 2012-01-11 Fdc Limited Oral controlled release dosage forms for water soluble drugs
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
RU2427389C2 (ru) * 2009-10-09 2011-08-27 Александр Владимирович Диковский Фармацевтическая композиция для профилактики и лечения инфекционных и неинфекционных диарей
EP2506714A4 (en) * 2009-11-30 2013-07-03 Aptalis Pharmatech Inc MOUTH ONDANSETRON TABLET COMPOSITIONS TO PREVENT EVIL AND CRUSH
BR112012015282A2 (pt) * 2009-12-22 2016-03-15 Abbott Healthcare Private Ltd composição farmacêutica de liberação controlada
CN102892405A (zh) 2009-12-28 2013-01-23 莫诺索尔克斯有限公司 包含昂丹司琼的可经口施用的膜剂型
US8916194B2 (en) 2010-08-30 2014-12-23 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
US20120128730A1 (en) * 2010-11-23 2012-05-24 Nipun Davar Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron
ES2946985T3 (es) 2013-03-14 2023-07-31 Redhill Biopharma Ltd Formas farmacéuticas sólidas antieméticas de liberación prolongada

Also Published As

Publication number Publication date
WO2014181195A3 (en) 2015-12-17
WO2014181195A2 (en) 2014-11-13
BR112015022398B1 (pt) 2022-01-11
PH12015502093B1 (en) 2018-09-26
EP2983664B1 (en) 2023-04-19
RU2015143993A3 (enExample) 2018-03-21
US20140271851A1 (en) 2014-09-18
MX378261B (es) 2025-03-10
EP2983664A4 (en) 2017-01-04
ES2946985T3 (es) 2023-07-31
AU2014264342B2 (en) 2017-05-18
MX2015012970A (es) 2016-04-11
US20180028452A1 (en) 2018-02-01
JP2016512493A (ja) 2016-04-28
KR20150127253A (ko) 2015-11-16
RU2679448C2 (ru) 2019-02-11
RU2015143993A (ru) 2017-04-20
CN112274489A (zh) 2021-01-29
KR102270521B1 (ko) 2021-06-30
US20170189340A1 (en) 2017-07-06
CA2905553A1 (en) 2014-11-13
ZA201506961B (en) 2017-03-29
PH12015502093A1 (en) 2016-01-18
EP2983664A2 (en) 2016-02-17
BR112015022398A8 (pt) 2019-11-26
BR112015022398A2 (pt) 2017-07-18
WO2014184662A3 (en) 2015-04-02
CA2905553C (en) 2021-04-06
US20140271887A1 (en) 2014-09-18
IL241580B (en) 2020-08-31
SG11201507450TA (en) 2015-10-29
WO2014184662A2 (en) 2014-11-20
NZ712159A (en) 2019-12-20
JP6282676B2 (ja) 2018-02-21
CN105530935A (zh) 2016-04-27
US9636305B2 (en) 2017-05-02
AU2014264342A1 (en) 2015-10-01
HK1223012A1 (zh) 2017-07-21
US20200330392A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
ECSP17029371A (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CR20150507A (es) Inhibidores de histona desmetilasas
NI201700034A (es) Indazoles sustituidos con benzilo como inhibidores de bub1.
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
CL2016001586A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
ECSP17015977A (es) Terapia de combinacion
TWD170102S (zh) 針盤
LT2981255T (lt) Empagliflozino terapiniai panaudojimo būdai
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
EP3736015C0 (en) Multi-unit drug delivery devices
BR112015029858A2 (pt) toalha sanitária
PT2953948T (pt) Antagonistas de integrina fluorada
BR112015028572A2 (pt) ventilador axial
PT2991633T (pt) Terapia com bacteriófagos
BR112015023511A2 (pt) tensor
EP2945942A4 (en) Voriconazole IMMUNOASSAY
MX2014015039A (es) Inhibidores de fbx03.
AR097668A1 (es) Colorante-polímero
BR112015032344A2 (pt) compostos isotiazolinas naftil- ou isoquinolinil-substituídos
CL2015002666A1 (es) Formas de dosificación sólidas de antiemético de liberación prolongada
BR112015023782A2 (pt) conjunto de polias
EP2988738A4 (en) THERAPEUTIC INDICATIONS OF KINASE INHIBITORS
BR112015024771A2 (pt) cateter
BR112015029634A2 (pt) argamassa polimérica
BR112015021575A2 (pt) composição fungicida